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Although mutations in the amyloid-b precursor protein (APP) gene are known to confer high risk of Alzheimer
disease (AD) to a small percentage of families in which it has early onset, convincing evidence of a major role for
the APP locus in late-onset AD has not been forthcoming. In this report, we have used a covariate-based affected-
sib-pair linkage method to analyze the chromosome 21 clinical and genetic data obtained on affected sibships by
the National Institute of Mental Health Alzheimer Disease Genetics Initiative. The baseline model (without covari-
ates) gave a LOD score of 0.02, which increases to 1.43 when covariates representing the additive effects of E2
and E4 are added. Larger increases in LOD scores were found when age at last examination/death (LOD score
5.54; ) or age at onset plus disease duration (LOD score 5.63; ) were included in thePp .000002 Pp .000006
linkage model. We conclude that the APP locus may predispose to AD in the very elderly.
Although mutations in the amyloid-b recursor protein
(APP [MIM 104760]) gene are known to confer high
risk of Alzheimer disease (AD [MIM 104300]) to a small
percentage of families in which it has early onset (Goate
et al. 1991), convincing evidence of a major role for the
APP locus in late-onset AD has not been forthcoming.
Recently, using affected sib pairs (ASPs) collected as part
of the National Institute of Mental Health Alzheimer
Disease (NIMH AD) Genetics Initiative (see the Alzhei-
mer Disease Genetics Initiative Data Archive web site),
Kehoe et al. (1999) and Wavrant-De Vrieze et al. (1999)
reported evidence that ASPs with no E4 allele at apo-
lipoprotein E (ApoE [MIM 107741]) were more likely
to show linkage to the APP region than were ASPs in
whom both members had at least one E4 allele. How-
ever, the effect that these authors detected was not large.
An independent genome scan of late-onset AD failed to
detect linkage to chromosome 21 (Pericak-Vance et al.
1997). To date, there has been little or no investigation
of possible associations between specific APP polymor-
phisms and late-onset AD.
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In this report, we revisit the data collected by theNIMH
ADGenetics Initiative (see the AlzheimerDiseaseGenetics
Initiative Data Archive web site) and analyze the chro-
mosome 21 data by using a covariate-based method of
ASP linkage analysis previously proposed by Goddard et
al. (2001). Specifically, we examine the roles of age at
onset (AAO), age at last examination or death, degree of
dementia, sex, and ApoE genotype in linkage to chro-
mosome 21. By including covariates in a linkage analysis,
one allows for locus heterogeneity due to those covariates
and thereby can discover linkage evidence that might oth-
erwise be obscured. In the present report, we show that
reanalysis of the NIMH AD data by a covariate-based
linkage model provides convincing evidence that the APP
locus plays a role in late-onset AD.
The collection, characterization, and genotyping of
AD-affected sibships by the NIMH AD Genetics Initia-
tive (see the Alzheimer Disease Genetics Initiative Data
Archive web site) have been described elsewhere (Blacker
et al. 1997). We restricted our analysis to 252 ASPs who
had onset at age 60 years and on whom there were
complete data for the following variables: AAO (con-
sidered to be the age at which the first symptoms were
present), current age (considered to be the age at either
the most recent examination [33%] or death [67%]),
sex, ApoE genotype, and degree of clinical dementia at
the time of examination (Hughes et al. 1982). The lower
bound on AAO was imposed to eliminate the possible
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Table 1
Descriptive Statistics of Variables and Covariates
VARIABLE OR COVARIATE
VALUE
WITHIN-PAIR
CORRELATIONMean (SD) Range
Original variables ( sibs):np 461
AAO 74.77 (5.84) 61–93
Current age 83.33 (6.72) 63–105
Duration 8.56 (4.65) 1–28
Dementia 2.89 (1.12) 1–5
Sex (proportion of females) .75
ApoE-allele frequencies:
E2 .024
E3 .581
E4 .395
Covariates ( ASPs):anp 252
AAO 149.02 (9.97) 127–181 .37
Current age 166.60 (11.93) 134–208 .55
Duration 17.58 (7.23) 4–44 .18
Dementia 5.78 (1.70) 2–10 .10
Sex (no. of females) 1.45 (.67) 0–2 .12
E4 (no. of E4 alleles) 1.63 (1.12) 0–4 .58
E2 (no. of E2 alleles) .08 (.34) 0–2 .25
Current age, by E4:
No E4 alleles ( )np 51 175.12 (11.78) 154–208
One E4 allele ( )np 52 167.50 (11.80) 143–192
Two E4 alleles ( )np 106 165.42 (10.03) 141–190
Three E4 alleles ( )np 26 159.19 (10.92) 134–179
Four E4 alleles ( )np 17 156.88 (8.70) 144–169
a Data are for the sum of the pairs’ values before centering; covariateswere centered before inclusion
in linkage models.
effect that outliers might have on the linkage analysis;
only four ASPs were removed for this reason. For AAO,
current age, disease duration (current age minus AAO),
and degree of dementia, the covariate included in the
linkage analysis was the sum of the values for the two
individuals. For sex, we counted the number of females
in the ASP. For ApoE genotype, we considered two cov-
ariates: (1) the total number of E4 alleles in the ASP and
(2) the total number of E2 alleles in the ASP.
To allow for covariate-related locus heterogeneity,
we applied a covariate-based ASP LOD-score method
(Goddard et al. 2001) to the genotype data for chro-
mosome 21. The model is a one-parameter modifica-
tion of the conditional logistic parameterization of the
ASP LOD score, a parameterization introduced by Ol-
son (1999). An optimal mode-of-inheritance parame-
ter (Whittemore and Tu 1998) is specified that allows
one to fit only a single additional parameter per covari-
ate. In terms of offspring recurrence-risk ratio, condi-
tional on K covariates, xk, the model is parameterized
as ; in terms of the recur-Kl (x)p exp (b S g x )1 kp1 k k
rence-risk ratio for MZ twins, it is parameterized as
.l (x)p 3.634l (x) 2.6342 1
This model has been implemented in the S.A.G.E.
program LODPAL (see The Human Genetic Analysis
Resource web site). To simplify specification of con-
straints on parameter estimates, all covariates are cen-
tered around their sample mean before being included
within the linkage model; asymptotic distributions of
the resulting likelihood-ratio tests were used to obtain
P values (see Goddard et al 2001). Covariate-specific
sibling recurrence-risk ratios can be obtained by the
expression .1 1 1l (x)p  l (x) l (x)S 1 24 2 4
In this report, we describe as “LOD” scores the like-
lihood-ratio statistics (LRSs) divided by 4.605 (i.e.,
2loge10). Critical values for the LRSs were obtained as
follows. The distribution of the LRS for the basic one-
parameter model is a 50:50 mixture of a point mass at
0 and a x2 distribution with 1 df. Addition of K covari-
ates gives an LRS with a distribution that is a 50:50
mixture of a x2 with K df and a x2 with df. TheK 1
LRS difference between nested models that differ by J
covariates has a x2 distribution with J df. One can there-
fore test both the significance of the contribution of a
covariate and the overall evidence for linkage.
Multipoint identity-by-descent values were computed
at 2-cM intervals throughout chromosome 21, with use
of all markers available from the genome scan. In this
report, we describe results at the approximate location
of the APP locus (2 cM proximal to D21S1435). It is
necessary, when testing the significance of covariates, to
compare models at the same chromosomal location; our
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Table 3
Recurrence-Risk Ratios, by Current
Age
Current Agea
(x/2)
No. of SD
Unitsb lS(x)
71.37 2 .33
77.33 1 .69
83.30 0 1.23
89.26 1 2.05
95.23 2 3.26
a Average, for an ASP.
b Above or below sample mean.
Table 2
LOD Scores, Parameter Estimates, and Significance Levels at the APP Locus
Model
LOD
Score b g1 g2 g3 g4 Overall P
LOD Score
Differencea Pa
Baseline .05 .0284 .3923 … …
Plus ApoE4 (E4) 1.13 .0402 .1131 .0483 1.08 .0257
Plus ApoE2 (E2) .36 .0383 .3314 .3172 .31 .2322
Plus E4 plus E2 1.43 .0539 .1089 .3778 .0618 .30 .2398
Plus sex .19 .0303 .0710 .4976 .14 .4220
Plus dementia .24 .0317 .0349 .4343 .19 .3496
Plus AAO 2.27 .0580 .0192 .0032 2.22 .0014
Plus current age 5.54 .1540 .0337 .000002 5.49 .0000005
Plus duration .64 .0370 .0136 .1576 .59 .0993
Plus AAO plus duration 5.63 .1523b .0324c .0361d .000006 3.36 .000084
Plus AAO plus duration plus E4 plus E2 5.70 .1569 .0334 .0364 .0198 .0909 .000054 .07 .5702
a Between this model and nearest nested model.
b Standard error .0877 (computed under the assumption that ASPs are independent).
c Standard error .0094 (computed under the assumption that ASPs are independent).
d Standard error .0010 (computed under the assumption that ASPs are independent).
peak LOD scores all occurred either at or close to (i.e.,
4 cM from) this location.
Table 1 contains descriptive statistics of the variables
used to construct covariates for the linkage analysis. In
the model, the covariates were included as the sum of
the values for the two individuals constituting each ASP;
table 1 also includes the means and SDs for these covari-
ates, as well as those for the original variables.
Table 2 contains the LOD scores at the APP locus.
The baseline LOD score, with no covariates, has a value
of only 0.02, showing no evidence of linkage. The LOD
score increases to 1.13 when E4 is added. These results
are consistent with what Wavrant-DeVrieze et al. (1999)
found by using these data; ASPs without E4 alleles show
the most evidence of linkage to the APP locus. The ad-
dition of E2 to the model is nonsignificant (i.e., a 0.30
increase in LOD score), possibly, at least in part, because
E2 is relatively rare both in the population in general
and in patients with AD (see table 1). However, it is
instructive to consider the fitted sibling recurrence-risk
ratios for this model, which show that the risk is lowest
in ASPs with four E4 alleles ( ), moderate inl p 0.71S
ASPs with four E3 alleles ( ), and highest inl p 1.32S
ASPs with two E2 and two E3 alleles ( ). Nol p 3.26S
ASP in this data set had more than two E2 alleles.
The most significant covariates were those that mea-
sured age. Inclusion of AAO increases the LOD score
to 2.27, and (separate) inclusion of current age increases
the LOD score to 5.54; the effects of both covariates
were highly significant. Current duration of disease (cur-
rent age minus AAO) shows little effect when included
separately but greatly increases the LOD score (to 5.63)
when included along with AAO. The signs of the covari-
ate parameters indicate that “linked” ASPs tend to be
those with the latest AAO and longest disease duration,
or, almost equivalently, the oldest current age.
The model with current age alone is the most parsi-
monious and may be most useful for identification and/
or ascertainment of ASPs most likely to be useful in
further studies of the role of APP in late-onset AD, par-
ticularly in searches for predisposing polymorphisms. In
table 3 we provide sibling recurrence-risk ratios for some
values of current age; these results suggest that future
searches for relevant APP polymorphisms should focus
on affected individuals in their late 80s and older. In
table 1 we also provide mean total current ages of ASPs,
by number of E4 alleles. Current age decreases with
increasing number of E4 alleles; individual patients in
ASPs with no E4 alleles are, on average, ∼10 years older
than those in ASPs with four E4 alleles.
To ensure that our result for the APP locus was not
the result of strong influence from a small number of
sib pairs, we obtained the ASP-specific LOD-score con-
tributions (a new feature of LODPAL) for the model
with AAO and disease duration. Sixty-eight ASPs had
LOD-score contributions 10.1, and 104 had LOD-score
contributions 10.1 in absolute value; the range was
0.76 to 0.55. We remaximized the LOD-score function
after eliminating the five ASPs whose contribution to the
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LOD score was 10.4 in absolute value. The resulting
LOD score, 5.02, although reduced in magnitude, re-
mains highly significant.
We have shown that the APP locus on chromosome
21 is strongly linked to AD if AAO plus disease duration
or current age alone are included as covariates in the
linkage model. The most parsimonious model includes
only current age; the longest-lived affected individuals
are most likely to have linkage to the APP region. In
addition, the model with AAO plus disease duration
suggests that ASPs susceptible to the detrimental effects
of mutations in the APP region are those with very late
onset who survive longer with the disease. It may be that
this form of AD is characterized by both very late onset
and slower disease progression, but, because the three
variables are linearly related, we cannot statistically de-
termine which of the two models best represents the
primary features. Our results are also consistent with (a)
Kehoe et al.’s (1999) and Wavrant-DeVrieze et al.’s
(1999) findings that these ASPs have fewer ApoE4 alleles
than do the rest of the sample and (b) Blacker et al.’s
(1997) results, based on the same data, suggesting that
ApoE4 exerts its maximal effect at age !70 years.
The absence of E4 alleles in these individuals may not
represent an interaction at the biological level. Because
these mutations in the APP region do not confer sus-
ceptibility until very late in life, most individuals with
E4 alleles may have either died or at least fallen ill with
E4-type AD prior to the age when these mutations be-
come penetrant. In addition, these individuals appear to
survive longer with the disease, suggesting a slower dis-
ease progression.
These results also demonstrate the usefulness of covar-
iate-based linkage methods for both detection of linkage
in the presence of locus heterogeneity and identification
of which subgroups of families have linkage to which
loci. In this report, we not only have established strong
evidence of linkage and age-related locus heterogeneity
but also have provided useful recommendations for sam-
ple selection or subselection in future research. Specifi-
cally, studies of the role that APP-region mutations play
in late-onset AD should concentrate on the extremely
elderly, particularly those with later AAO who have sur-
vived longer than average and, perhaps incidentally, have
few E4 alleles. As have Goddard et al. (2001), we note
that the ability to include covariates increases the overall
probability of type I errors due to multiple analyses of
the same genetic data. In this report, we have used ge-
nomewide significance levels associated with a single
analysis but have focused our attention exclusively on
chromosome 21, with the exception of the E4 variable,
as noted below. In general, we recommend both careful
prior selection of covariates and genomic regions for
study and cautious interpretation of results.
It may be noted that, because disease duration adds
considerably to the LOD score at the APP locus, even
after AAO is taken into account, samples ascertained
through new AD cases might not be as useful for stud-
ying the APP effect as are samples ascertained through
a cohort of existing cases, even if only families with very
late onset are collected. In cohort sampling, the effects
of length-biased sampling would likely lead to oversam-
pling of patients with APP-type symptoms, with respect
to their incidence rates, but that would be desirable if
one wished to “load” one’s sample for families most
likely to carry mutations in the APP region. It also should
be noted that, in these data, disease duration is measured
by subtracting AAO from age at last examination, if age
at death is not available, and that it therefore represents
disease duration until the time at most recent observa-
tion. On the other hand, age at death was available for
approximately two-thirds of these patients. It is difficult
to know precisely either how our quantitative measure-
ment of disease duration is affected by the ascertainment
scheme or how these results might change if age at death
of all of these affected individuals were available.
We rescanned the entire genome, using a linkage
model that includes our E4 covariate (results not shown).
Other than the APP region, no genomic location—
including the regions on chromosomes 6, 9, 10, and 19,
previously reported on the basis of these data (Kehoe et
al. 1999; Bertram et al. 2000; Collins et al. 2000; Myers
et al. 2000), and the region, on chromosome 12, pre-
viously reported, by Pericak-Vance et al. (1997), for a
different data set—provided even modest evidence that
ASPs with fewer E4 alleles were more strongly linked
than were families with more E4 alleles. On the other
hand, regions on chromosomes 1p21, 2, 4, 5, 9, 14pter,
16, and 19 each showed some evidence (i.e., LOD score,
for covariate effect, .74–1.94) that ASPs with more E4
alleles were more likely to be linked than were ASPs
with fewer E4 alleles. These results suggest that E4 alleles
may play a role in many, but not all, biological mech-
anisms that lead to AD.
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